Visiongain’s new study predicts that the overall market for medicines to treat and manage unusual Central Nervous System (CNS) disorders will expand from 2014 to 2024. The strength of this pharma segment stems from incentives in orphan drug development, including regulatory filing and first-mover advantages and protection. Also, despite small patient numbers, pharma companies can expect steady demand for a drug after approvals and commercial launches. Strong prospects exist. (Source: visiongain, “World Market For Orphan CNS Drugs Will Exceed $2.5BN in 2018?' , 2014) SMi's masterclass hosted by QCTR will look at the challenges and potential advantages of developing drugs in CNS orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in orphan diseases. It will look at case studies of drug companies who have followed this route. Key benefits to this masterclass are: • This masterclass is essential attendance for anyone who wants to understand clinical trials in a rare CNS disease • Gain timely insight into key trial design strategies • Discover the benefits of orphan disease regulations • Learn from real-life case studies of how companies have approached these challenges